Thorsten Lubinski, co-founder and CEO of DiaMonTech
Disrupt Health Impact Fund, a Thailand-based venture capital fund focused on healthcare innovation, has announced its first investment in DiaMonTech, a German deeptech startup specializing in non-invasive glucose monitoring.
The fund will provide DiaMonTech connections with healthcare experts in the public and private sectors across Southeast Asia and facilitate its entry into the region. It will also accelerate the startup’s ability to reach a wider audience and make its technology accessible to more needy people.
Thorsten Lubinski, co-founder and CEO of DiaMonTech, said: “This support will enable expansion and connection to meaningful opportunities that positively impact people living with diabetes and those monitoring their blood sugar for preventive healthcare throughout Southeast Asia, including Thailand.”
Also Read: 500 TukTuks, ORZON Ventures execs launch Disrupt Health Impact Fund in Thailand
DiaMonTech has developed technology that measures blood glucose levels without the need for painful finger pricking. This empowers individuals to take control of their diabetes management and make more informed decisions about their health.
Its non-invasive approach offers a “significant advantage” over traditional blood glucose monitoring methods, which require frequent finger pricking and can be inconvenient and painful for patients.
The device uses a spectroscopic method to measure glucose levels through the skin, providing a reading in just 30 seconds.
The technology could also be used for preventive healthcare, enabling early detection of prediabetes and potentially delaying or preventing the onset of type 2 diabetes.
The investment in DiaMonTech aligns with Disrupt Health Impact Fund’s focus on investing in five key areas: Self-care, preventive care, silver age, holistic wellness, and Smart Hospital.
The post Disrupt Health invests in DiaMonTech’s non-invasive glucose monitoring tech appeared first on e27.